Table 2.
SLE-DK (plasma) |
SLE-SE (plasma) |
SLE-INF-α (serum) |
|||||||
---|---|---|---|---|---|---|---|---|---|
n | r | p Value | n | r | p Value | n | r | p Value | |
Age | 70 | −0.32 | 0.01 | 68 | 0.0018 | 0.99 | 26 | −0.16 | 0.43 |
Nephritis* | 70 | 0.14 | 0.24 | 68 | 0.049 | 0.69 | 26 | 0.42 | 0.03 |
SLEDAI* | 70 | 0.41 | 0.0004 | 68 | −0.0025 | 0.98 | 26 | 0.38 | 0.05 |
SLICC/ACR Damage Index | 70 | −0.08 | 0.53 | 68 | 0.036 | 0.77 | N/A | ||
Immunosuppressive treatment† | 70 | −0.05 | 0.68 | 68 | 0.052 | 0.68 | 26 | 0.29 | 0.16 |
ESR | 66 | 0.57 | <0.0001 | N/A | N/A | ||||
Haemoglobin | 70 | −0.29 | 0.02 | 68 | −0.21 | 0.08 | 26 | 0.17 | 0.41 |
Neutrophils | 70 | −0.36 | 0.002 | 67 | 0.037 | 0.77 | N/A | ||
Lymphocytes | 70 | −0.04 | 0.72 | 67 | −0.084 | 0.50 | 26 | 0.11 | 0.58 |
Platelets | 70 | −0.02 | 0.85 | N/A | 26 | −0.06 | 0.78 | ||
Anti-dsDNA | 69 | 0.35 | 0.003 | 68 | −0.094 | 0.45 | 26 | 0.54 | 0.005 |
Anti-Sm | 69 | 0.26 | 0.03 | 68 | 0.0021 | 0.99 | N/A | ||
Anti-Ro | 69 | 0.32 | 0.01 | N/A | N/A | ||||
Anti-La | 69 | 0.25 | 0.04 | N/A | N/A | ||||
C3 low | 69 | −0.03 | 0.78 | 68 | 0.095 | 0.44 | 26 | −0.30 | 0.14 |
C4 low | 69 | −0.09 | 0.45 | 68 | 0.14 | 0.26 | 26 | −0.28 | 0.17 |
Bold denotes significant observations (p<0.05). *All of the clinical manifestations included in the SLEDAI were tested and no other significant correlations were detected.
†At inclusion. Immunosuppressive treatment included prednisolone, methotrexate, mycophenylate mofetil, azathioprine and plaquenil.
C3, complement component C3; C4, complement component C4; DK, Denmark; ESR, erythrocyte sedimentation rate; N/A, not available; IFN-α, interferon-α; SE, Sweden; SLEDAI, Systemic Lupus Erythematosus Disease Activity Index; SLICC/ACR, Systemic Lupus International Collaborating Clinics/American College of Rheumatology.